Celgene Corp (NASDAQ:CELG)

During the Trading Day
118.22 +2.48 / +2.15%
As of 4:14pm ET
Day’s Change
During After-Hours   Switch to standard view »
118.35 +0.13 / +0.11%
Volume: 98.1K
Health Technology

Company Description

Celgene Corp. engages in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. It is dedicated to innovative research and development, which is designed to bring new therapies to market and is involved in research in several scientific areas such as immunomodulation and intracellular signaling pathways in hematology, oncology and immune-inflammatory diseases. Its portfolio of commercial products include Revlimid, Vidaza, Thalomid, Pomalyst/Imnovid, Abraxane, and Istodax. Celgene was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

Contact Information

Celgene Corp.
86 Morris Avenue
Summit New Jersey 07901
P:(908) 673-9000
Investor Relations:
(908) 673-9969



Mutual fund holders43.57%
Other institutional39.84%
Individual stakeholders1.22%

Top Executives

Robert J. HuginChairman & Chief Executive Officer
Mark J. AllesPresident & Chief Operating Officer
Peter N. KelloggChief Financial Officer & Executive Vice President
Jerome Bernard ZeldisChief Medical Officer & CEO-Global Health
Thomas O. DanielEVP, President-Research & Early Development

To view my watchlist

Not a member yet?

Sign up now for a free account